GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Dermapharm Holding SE (XTER:DMP) » Definitions » Return-on-Tangible-Asset

Dermapharm Holding SE (XTER:DMP) Return-on-Tangible-Asset : 13.21% (As of Mar. 2025)


View and export this data going back to 2018. Start your Free Trial

What is Dermapharm Holding SE Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Dermapharm Holding SE's annualized Net Income for the quarter that ended in Mar. 2025 was €134 Mil. Dermapharm Holding SE's average total tangible assets for the quarter that ended in Mar. 2025 was €1,011 Mil. Therefore, Dermapharm Holding SE's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2025 was 13.21%.

The historical rank and industry rank for Dermapharm Holding SE's Return-on-Tangible-Asset or its related term are showing as below:

XTER:DMP' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 5.65   Med: 15.62   Max: 35.25
Current: 9.95

During the past 12 years, Dermapharm Holding SE's highest Return-on-Tangible-Asset was 35.25%. The lowest was 5.65%. And the median was 15.62%.

XTER:DMP's Return-on-Tangible-Asset is ranked better than
81.12% of 1022 companies
in the Drug Manufacturers industry
Industry Median: 2.655 vs XTER:DMP: 9.95

Dermapharm Holding SE Return-on-Tangible-Asset Historical Data

The historical data trend for Dermapharm Holding SE's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dermapharm Holding SE Return-on-Tangible-Asset Chart

Dermapharm Holding SE Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Return-on-Tangible-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 14.18 27.79 15.94 6.66 11.22

Dermapharm Holding SE Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 16.66 6.40 12.19 8.14 13.21

Competitive Comparison of Dermapharm Holding SE's Return-on-Tangible-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Dermapharm Holding SE's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Dermapharm Holding SE's Return-on-Tangible-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Dermapharm Holding SE's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Dermapharm Holding SE's Return-on-Tangible-Asset falls into.


;
;

Dermapharm Holding SE Return-on-Tangible-Asset Calculation

Dermapharm Holding SE's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2024 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2024 )  (A: Dec. 2023 )(A: Dec. 2024 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2024 )  (A: Dec. 2023 )(A: Dec. 2024 )
=113.787/( (1037.29+991.321)/ 2 )
=113.787/1014.3055
=11.22 %

Dermapharm Holding SE's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2025 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Mar. 2025 )  (Q: Dec. 2024 )(Q: Mar. 2025 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Mar. 2025 )  (Q: Dec. 2024 )(Q: Mar. 2025 )
=133.62/( (991.321+1031.21)/ 2 )
=133.62/1011.2655
=13.21 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Mar. 2025) net income data.


Dermapharm Holding SE  (XTER:DMP) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Dermapharm Holding SE Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of Dermapharm Holding SE's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Dermapharm Holding SE Business Description

Traded in Other Exchanges
Address
Lil-Dagover-Ring 7, Grunwald, BY, DEU, 82031
Dermapharm Holding SE manufactures patent-free branded pharmaceuticals for selected therapy fields, over-the-counter drugs, and natural remedies. The portfolio of the company includes cosmetics, nutritional supplements, and diet and medical devices. Business operating segments include Branded pharmaceuticals, which drive key revenue, Other healthcare products, and Parallel import business. The Branded pharmaceuticals segment covers numerous product areas through a wide variety of items sold under reputable brand names.
Executives
Wilhelm Beier Supervisory Board
Dr. Hans-georg Feldmeier Board of Directors
Christof Dreibholz Board of Directors
Lothar Lanz Supervisory Board
Anja Schorn Board Member Themis Beteiligungs-AG
Hilde Neumeyer Board of Directors

Dermapharm Holding SE Headlines

No Headlines